at Zacks.com (Tue, 6:50PM)
Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%) courtship, apparently after being rebuffed in reaching out to other possible buyers including Pfizer (PFE), Johnson & Johnson (JNJ) and Merck (MRK). Currently under discussion: a CVR that would give Genzyme upside if leukemia drug Campath proves effective against MS.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 23, 2015)
at Zacks.com (Jan 20, 2015)
at Benzinga.com (Jan 15, 2015)
at Zacks.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs